T/R ratio for estimation of sample size in BE study of NTI drugs [Power / Sample Size]

posted by Helmut Homepage – Vienna, Austria, 2017-10-25 01:15 (2365 d 21:09 ago) – Posting: # 17917
Views: 7,151

Salam Mahmoud,

❝ Pease, advise me about what is the best T/R ratio to be used for estimating sample size for a BE study of NTI drugs? knowing that the GL to be followed set the 90% CI acceptance range to (90-111.11) for Cmax if a "2x2x2" design be followed.

❝ I'm confused to use T/R ratio of 0.95 or 0.975?!


Both are fine. Note that the FDA requires tighter batch release spec’s for NTIDs. Hence, in function sampleN.NTIDFDA() of PowerTOST the default is 0.975 – contrary to the usual 0.95.

library(PowerTOST)
sampleN.NTIDFDA(CV=0.0945)

+++++++++++ FDA method for NTID's +++++++++++
           Sample size estimation
---------------------------------------------
Study design:  2x2x4
log-transformed data (multiplicative model)
1e+05 studies for each step simulated.

alpha  = 0.05, target power = 0.8
CVw(T) = 0.0945, CVw(R) = 0.0945
True ratio     = 0.975
ABE limits     = 0.8 ... 1.25
Implied scABEL = 0.9054 ... 1.1044
Regulatory settings: FDA
- Regulatory const. = 1.053605
- 'CVcap'           = 0.2142

Sample size search
 n     power
16   0.777210
18   0.831050

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,654 registered users;
53 visitors (0 registered, 53 guests [including 5 identified bots]).
Forum time: 22:25 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5